ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,770.20
0.55%
Dow Jones
42,801.72
0.52%
US Dollar vs MXN
20.26717
0.00%
Brent Oil
70.235
0.00%
Bitcoin
82,555.43
-4.19%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Noticias

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:NTLA
FechaHoraFuenteTítuloSímboloCompañía
06/03/202504:45PR Newswire (US)The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLANASDAQ:NTLAIntellia Therapeutics Inc
04/03/202515:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
04/03/202515:01GlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
03/03/202504:45PR Newswire (US)NTLA LAWSUIT ALERT: The Gross Law Firm Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNASDAQ:NTLAIntellia Therapeutics Inc
28/02/202515:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NTLAIntellia Therapeutics Inc
27/02/202515:03Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NTLAIntellia Therapeutics Inc
27/02/202506:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
27/02/202506:30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
27/02/202504:45PR Newswire (US)The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLANASDAQ:NTLAIntellia Therapeutics Inc
24/02/202504:45PR Newswire (US)Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - NTLANASDAQ:NTLAIntellia Therapeutics Inc
20/02/202506:30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
20/02/202504:45PR Newswire (US)The Gross Law Firm Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming DeadlineNASDAQ:NTLAIntellia Therapeutics Inc
23/01/202516:41Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
22/01/202506:30GlobeNewswire Inc.Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
09/01/202515:00GlobeNewswire Inc.Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)NASDAQ:NTLAIntellia Therapeutics Inc
25/11/202406:30GlobeNewswire Inc.Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with PolyneuropathyNASDAQ:NTLAIntellia Therapeutics Inc
16/11/202409:16GlobeNewswire Inc.Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) AmyloidosisNASDAQ:NTLAIntellia Therapeutics Inc
07/11/202415:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NTLAIntellia Therapeutics Inc
07/11/202406:30GlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
31/10/202406:30GlobeNewswire Inc.Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024NASDAQ:NTLAIntellia Therapeutics Inc
24/10/202407:01GlobeNewswire Inc.Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
10/10/202406:30GlobeNewswire Inc.Intellia Therapeutics Announces New Date for Upcoming Investor WebcastNASDAQ:NTLAIntellia Therapeutics Inc
07/10/202406:30GlobeNewswire Inc.Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
01/10/202406:30GlobeNewswire Inc.Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific SessionsNASDAQ:NTLAIntellia Therapeutics Inc
12/09/202406:30GlobeNewswire Inc.Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific MeetingNASDAQ:NTLAIntellia Therapeutics Inc
08/08/202406:30GlobeNewswire Inc.Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
01/08/202406:30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
30/07/202406:30GlobeNewswire Inc.Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin DeficiencyNASDAQ:NTLAIntellia Therapeutics Inc
02/07/202411:53PR Newswire (US)Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law FirmNASDAQ:NTLAIntellia Therapeutics Inc
26/06/202406:30GlobeNewswire Inc.Intellia Therapeutics Announces CFO TransitionNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Su Consulta Reciente

CCOM
SILVER
SILVER
COIN
ADAUSD
Cardano
NASDAQ
NVDA
NVIDIA
COIN
AVAXUSD
Avalanche
NASDAQ
AAPL
Apple
NYSE
XOM
Exxon Mobil
AMEX
XLF
Financial Select Sector
USOTC
BNPQY
BNP Paribas (QX)
USI
USTECH100
US Tech 100
NYSE
MCD
McDonalds
CCOM
US500
US 500
PM
XAUUSD
Gold vs US Dollar
FX
USDMXN
US Dollar vs MXN
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
AMZN
Amazon.com
COIN
BTCUSD
Bitcoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios